Serum IF1 concentration is independently associated to HDL levels and to coronary heart disease: The GENES study

Journal of Lipid Research

Volumn 54, Issue 9, 2013, Pages 2550-2558

  Genoux, Annelise ^a,b,d   Ruidavets, Jean Bernard ^a   Ferrières, Jean ^a,c   Combes, Guillaume ^a,b   Lichtenstein, Laeticia ^a,b   Pons, Véronique ^a,b   Laffargue, Muriel ^a,b   Taraszkiewicz, Dorota ^a   Carrié, Didier ^c   Elbaz, Meyer ^c   Perret, Bertrand ^a,b,d   Martinez, Laurent O ^a,b  

^a INSERM   (France)

^b University Hospital of Toulouse   (France)

^c CHU RANGUEIL   (France)

^d CHU PURPAN   (France)

Author keywords

ATP synthase inhibitor factor 1; Coronary heart disease; HDL cholesterol; Inhibitor factor 1; Nucleotide receptor P2Y13

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INHIBITOR FACTOR 1; MITOCHONDRIAL PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE MARKER; HIGH DENSITY LIPOPROTEIN BLOOD LEVEL; HUMAN; INHIBITOR FACTOR 1 BLOOD LEVEL; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT;

ATP-SYNTHASE INHIBITOR FACTOR 1; CORONARY HEART DISEASE; HDL-CHOLESTEROL; INHIBITOR FACTOR 1; NUCLEOTIDE RECEPTOR P2Y13;

AGED; BIOLOGICAL MARKERS; CORONARY DISEASE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PROTEINS; RISK ASSESSMENT;

EID: 84883173427     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P036335     Document Type: Article

References (39)

1. Navab, M., S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman. 2011. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8: 222-232.
2. Francis, G. A. 2010. The complexity of HDL. Biochim. Biophys. Acta. 1801: 1286-1293.
3. Barter, P., A. M. Gotto, J. C. LaRosa, J. Maroni, M. Szarek, S. M. Grundy, J. J. P. Kastelein, V. Bittner, and J-C. Fruchart. 2007. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357: 1301-1310.
4. Boden, W. E., J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365: 2255-2267.
5. Schwartz, G. G., A. G. Olsson, M. Abt, C. M. Ballantyne, P. J. Barter, J. Brumm, B. R. Chaitman, I. M. Holme, D. Kallend, L. a. Leiter, et al. 2012. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367: 2089-2099.
6. Camont, L., M. J. Chapman, and A. Kontush. 2011. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol. Med. 17: 594-603.
7. Calabresi, L., M. Gomaraschi, and G. Franceschini. 2010. Highdensity lipoprotein quantity or quality for cardiovascular prevention? Curr. Pharm. Des. 16: 1494-1503.
8. Martinez, L. O., S. Jacquet, J. P. Esteve, C. Rolland, E. Cabezon, E. Champagne, T. Pineau, V. Georgeaud, J. E. Walker, F. Terce, et al. 2003. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature. 421: 75-79.
9. Jacquet, S., C. Malaval, L. O. Martinez, K. Sak, C. Rolland, C. Perez, M. Nauze, E. Champagne, F. Terce, C. Gachet, et al. 2005. The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. Cell. Mol. Life Sci. 62: 2508-2515.
10. Fabre, A. C., C. Malaval, A. Ben Addi, C. Verdier, V. Pons, N. Serhan, L. Lichtenstein, G. Combes, T. Huby, F. Briand, et al. 2010. P2Y13 receptor is critical for reverse cholesterol transport. Hepatology. 52: 1477-1483.
11. Blom, D., T. T. Yamin, M. F. Champy, M. Selloum, E. Bedu, E. Carballo-Jane, L. Gerckens, S. Luell, R. Meurer, J. Chin, et al. 2010. Altered lipoprotein metabolism in P2Y(13) knockout mice. Biochim. Biophys. Acta. 1801: 1349-1360.
12. Rothblat, G. H., and M. C. Phillips. 2010. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol. 21: 229-238.
13. Pullman, M. E., and G. C. Monroy. 1963. A naturally occurring inhibitor of mitochondrial adenosine triphosphatase. J. Biol. Chem. 238: 3762-3769.
14. Genoux, A., V. Pons, C. Radojkovic, F. Roux-Dalvai, G. Combes, C. Rolland, N. Malet, B. Monsarrat, F. Lopez, J-B. B. Ruidavets, et al. 2011. Mitochondrial inhibitory factor 1 (IF1) is present in human serum and is positively correlated with HDL-cholesterol. PLoS ONE. 6: e23949.
15. Bouisset, F., V. Bongard, J-B. Ruidavets, S. Hascoët, D. Taraszkiewicz, J. Roncalli, D. Carrié, M. Galinier, M. Elbaz, and J. Ferrières. 2012. Prognostic usefulness of clinical and subclinical peripheral arterial disease in men with stable coronary heart disease. Am. J. Cardiol. 110: 197-202.
16. Hascoet, S., M. Elbaz, V. Bongard, F. Bouisset, C. Verdier, C. Vindis, A. Genoux, D. Taraszkiewicz, B. Perret, M. Galinier, et al. 2013. Adiponectin and long-term mortality in coronary artery disease participants and controls. Arterioscler. Thromb. Vasc. Biol. 33: e19-e29.
17. Friedewald, W. T., R. I. Levy, and D. S. Fredrickson. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18: 499-502.
18. Harrell, F. E., K. L. Lee, and D. B. Mark. 1996. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15: 361-387.
19. DeLong, E. R., D. M. DeLong, and D. L. Clarke-Pearson. 1988. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 44: 837-845.
20. Vaisar, T. 2012. Proteomics investigations of HDL: challenges and promise. Curr. Vasc. Pharmacol. 10: 410-421.
21. Shah, A. S., L. Tan, J. Lu Long, and W. S. Davidson. The proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. Epub ahead of print. February 24, 2013; doi:10.1194/jlr.R035725.
22. Cabezon, E., I. Arechaga, P. Jonathan, G. Butler, and J. E. Walker. 2000. Dimerization of bovine F1-ATPase by binding the inhibitor protein, IF1. J. Biol. Chem. 275: 28353-28355.
23. Cabezon, E., M. G. Montgomery, A. G. Leslie, and J. E. Walker. 2003. The structure of bovine F1-ATPase in complex with its regulatory protein IF1. Nat. Struct. Biol. 10: 744-750.
24. Vantourout, P., C. Radojkovic, L. Lichtenstein, V. Pons, E. Champagne, and L. O. Martinez. 2010. Ecto-F 1 -ATPase: a moonlighting protein complex and an unexpected apoA-I receptor. World J. Gastroenterol. 16: 5925-5935.
25. Trigatti, B., A. Rigotti, and M. Krieger. 2000. The role of the highdensity lipoprotein receptor SR-BI in cholesterol metabolism. Curr. Opin. Lipidol. 11: 123-131.
26. Large, V., O. Peroni, D. Letexier, H. Ray, and M. Beylot. 2004. Metabolism of lipids in human white adipocyte. Diabetes Metab. 30: 294-309.
27. Arakaki, N., T. Kita, H. Shibata, and T. Higuti. 2007. Cell-surface H+-ATP synthase as a potential molecular target for anti-obesity drugs. FEBS Lett. 581: 3405-3409.
28. Cortes-Hernandez, P., L. Dominguez-Ramirez, A. Estrada-Bernal, D. G. Montes-Sanchez, A. Zentella-Dehesa, M. T. de Gomez-Puyou, A. Gomez-Puyou, and J. J. Garcia. 2005. The inhibitor protein of the F1F0-ATP synthase is associated to the external surface of endothelial cells. Biochem. Biophys. Res. Commun. 330: 844-849.
29. Contessi, S., M. Comelli, S. Cmet, G. Lippe, and I. Mavelli. 2007. IF(1) distribution in HepG2 cells in relation to ecto-F(0)F (1) ATPsynthase and calmodulin. J. Bioenerg. Biomembr. 39: 291-300.
30. Giorgio, V., E. Bisetto, R. Franca, D. A. Harris, S. Passamonti, and G. Lippe. 2010. The ectopic F(O)F(1) ATP synthase of rat liver is modulated in acute cholestasis by the inhibitor protein IF1. J. Bioenerg. Biomembr. 42: 117-123.
31. Hassinen, I. E., K. H. Vuorinen, K. Ylitalo, and A. Ala-Rämi. 1998. Role of cellular energetics in ischemia-reperfusion and ischemic preconditioning of myocardium. Mol. Cell. Biochem. 184: 393-400.
32. Penna, C., P. Pagliaro, R. Rastaldo, F. Di Pancrazio, G. Lippe, D. Gattullo, D. Mancardi, M. Samaja, G. Losano, and I. Mavelli. 2004. F0F1 ATP synthase activity is differently modulated by coronary reactive hyperemia before and after ischemic preconditioning in the goat. Am. J. Physiol. Heart Circ. Physiol. 287: H2192-H2200.
33. von Eckardstein, A., M. Hersberger, and L. Rohrer. 2005. Current understanding of the metabolism and biological actions of HDL. Curr. Opin. Clin. Nutr. Metab. Care. 8: 147-152.
34. Mineo, C., H. Deguchi, J. H. Griffin, and P. W. Shaul. 2006. Endothelial and antithrombotic actions of HDL. Circ. Res. 98: 1352-1364.
35. Rader, D. J. 2007. Illuminating HDL - is it still a viable therapeutic target? N. Engl. J. Med. 357: 2180-2183.
36. Vergès, B., E. Florentin, S. Baillot-Rudoni, J-M. Petit, M. C. Brindisi, J-P. Pais de Barros, L. Lagrost, P. Gambert, and L. Duvillard. 2009. Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. J. Lipid Res. 50: 1209-1215.
37. Nieland, T. J., M. Penman, L. Dori, M. Krieger, and T. Kirchhausen. 2002. Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc. Natl. Acad. Sci. USA. 99: 15422-15427.
38. Masson, D., M. Koseki, M. Ishibashi, C. J. Larson, S. G. Miller, B. D. King, and A. R. Tall. 2009. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler. Thromb. Vasc. Biol. 29: 2054-2060.
39. Zhang, L. H., V. S. Kamanna, M. C. Zhang, and M. L. Kashyap. 2008. Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J. Lipid Res. 49: 1195-1201.